May 16 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive announces rights offering to fund the clinical
development of Bucillamine for the treatment of Cystinuria
Source text for Eikon: ID:nCCN1bckfY
Further company coverage: RVV.V
(Bengaluru Newsroom: +1-646-223-8780)